相关实验视频

Updated: Sep 11, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

伦瓦提尼布加帕克利塔塞尔作为高级胃癌患者的二线疗法:剂量升级探索性研究

Chenfei Zhou¹, Jinling Jiang¹, Liting Guo¹

¹Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

|August 11, 2025

概括

伦瓦提尼布加上帕克利塔塞尔显示出有希望的疗效和良好的耐受性,作为晚期胃癌 (AGC) 的二线治疗. 一个新的动态网络生物标记 (DNB) 评分可以预测患者的预后和对这种向治疗的反应.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
生物标志物生物标志物

背景情况:

晚期胃癌 (AGC) 的二线治疗选择有限.
伦瓦提尼布是一种多位氨酸激酶抑制剂 (TKI),与帕克利塔塞尔结合,正在研究AGC.
动态网络生物标志物 (DNB) 分析提供了一种新的方法来识别预测生物标志物.

研究的目的:

在AGC患者中确定伦瓦提尼布加帕克利塔塞尔的最大耐受剂量 (MTD).
使用DNB分析探索分子生物标志物,以预测预后和治疗反应.
评估这种联合治疗的安全性和有效性.

主要方法:

剂量升级研究使用lenvatinib的"3 + 3"设计.
患者接受了伦瓦提尼布加上帕克利塔塞尔 (135 mg/m2,q3w).
用奥林克蛋白质组学数据对连续血液样本进行了DNB分析.

主要成果:

伦瓦替尼的MTD被确定为16毫克.
这种组合耐受性良好,等级≥3不良事件发生率为18.2%.
客观应答率为36.4%,平均总生存时间为7.4个月. 建立了一个DNBscore,并与预后和反应相关联.

结论:

伦瓦提尼布加上帕克利塔塞尔显示出有前途的安全性和有效性,作为AGC的二线治疗.
DNBscore显示了作为这种组合治疗的预测生物标志物的潜力.
对DNB的进一步研究可以为AGC的向治疗提供关键的见解.

关键词:

剂量升级剂量的升级.动态网络生物标志物生物标志物胃癌胃癌是一种胃癌.伦瓦提尼布,二线药物.

更多相关视频

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...